Sign up to save your podcasts
Or
Share Current Treatment Landscape of Advanced Gastric/Esophageal/GEJ Adenocarcinoma – Dr. Rutika Mehta
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Current Treatment Landscape of Advanced Gastric/Esophageal/GEJ Adenocarcinoma – Dr. Rutika Mehta
Welcome to the Oncology Brothers podcast! In this episode, we were joined by Dr. Rutika Mehta, a GI medical oncologist from Weill Cornell. Together, we dived into the current treatment landscape for advanced metastatic gastroesophageal junction (GEJ) and gastrointestinal carcinoma, with a special focus on HER2-positive disease.
Episode Highlights:
• Overview of recent advancements in the treatment of resectable disease, including the approval of Durvalumab in perioperative settings.
• Discussion on the importance of biomarker testing, including HER2, PD-L1, MMR, and Claudin 18.2, in determining treatment options.
• Insights into frontline treatment strategies for HER2-positive patients, including the role of trastuzumab and the addition of pembrolizumab based on PD-L1 status.
• The significance of retesting HER2 expression upon disease progression and the implications for treatment decisions.
• Exploration of emerging therapies like TDXd and Zanidatamab, and their potential impact on the treatment landscape.
• Considerations for managing side effects and the importance of treatment sequencing in palliative care.
Join us for an informative discussion that aims to keep community oncologists up to date in this ever-evolving field of cancer treatment.
Follow us on social media:
• X/Twitter: https://twitter.com/oncbrothers
• Instagram: https://www.instagram.com/oncbrothers
• Website: https://oncbrothers.com/
Don't forget to subscribe for more episodes covering treatment algorithms, FDA approvals, and conference highlights!
Accreditation/Credit Designation
Physicians’ Education Resource®, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Physicians’ Education Resource®, LLC designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Acknowledgment of Commercial Support
This activity is supported by an educational grant from Jazz Pharmaceuticals, Inc.
Link to gain CME credits from this activity:
https://www.gotoper.com/courses/biomarker-testing-in-her2-gea-diagnosis-and-treatment-implications
#HER2GastricCancer #GastricCancer #BiomarkerTesting #OncologyBrothers #GIOncology #CME
View all episodes
By Oncology Brothers
4.9
4242 ratings
Welcome to the Oncology Brothers podcast! In this episode, we were joined by Dr. Rutika Mehta, a GI medical oncologist from Weill Cornell. Together, we dived into the current treatment landscape for advanced metastatic gastroesophageal junction (GEJ) and gastrointestinal carcinoma, with a special focus on HER2-positive disease.
Episode Highlights:
• Overview of recent advancements in the treatment of resectable disease, including the approval of Durvalumab in perioperative settings.
• Discussion on the importance of biomarker testing, including HER2, PD-L1, MMR, and Claudin 18.2, in determining treatment options.
• Insights into frontline treatment strategies for HER2-positive patients, including the role of trastuzumab and the addition of pembrolizumab based on PD-L1 status.
• The significance of retesting HER2 expression upon disease progression and the implications for treatment decisions.
• Exploration of emerging therapies like TDXd and Zanidatamab, and their potential impact on the treatment landscape.
• Considerations for managing side effects and the importance of treatment sequencing in palliative care.
Join us for an informative discussion that aims to keep community oncologists up to date in this ever-evolving field of cancer treatment.
Follow us on social media:
• X/Twitter: https://twitter.com/oncbrothers
• Instagram: https://www.instagram.com/oncbrothers
• Website: https://oncbrothers.com/
Don't forget to subscribe for more episodes covering treatment algorithms, FDA approvals, and conference highlights!
Accreditation/Credit Designation
Physicians’ Education Resource®, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Physicians’ Education Resource®, LLC designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Acknowledgment of Commercial Support
This activity is supported by an educational grant from Jazz Pharmaceuticals, Inc.
Link to gain CME credits from this activity:
https://www.gotoper.com/courses/biomarker-testing-in-her2-gea-diagnosis-and-treatment-implications
#HER2GastricCancer #GastricCancer #BiomarkerTesting #OncologyBrothers #GIOncology #CME
More shows like Oncology Brothers: Practice-Changing Cancer Discussions
View all
Journal of Clinical Oncology (JCO) Podcast
39 Listeners
Research To Practice | Oncology Videos
120 Listeners
ASCO Daily News
58 Listeners
Pod Save America
87,249 Listeners
Core IM | Internal Medicine Podcast
1,148 Listeners
The ONS Podcast
206 Listeners
OncoPharm
187 Listeners
ASCO Guidelines
45 Listeners
OncLive® On Air
22 Listeners
Lung Cancer Considered
26 Listeners
Oncology Today with Dr Neil Love
57 Listeners
Oncology On The Go
4 Listeners
Blood Cancer Talks
51 Listeners
Two Onc Docs
192 Listeners
Oncology for the Inquisitive Mind
4 Listeners